3 June 2022 - The Biosafety Advisory Council issues a positive advice (with conditions) for this deliberate release
File:
Trial reference:
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with ezabenlimab in patients with advanced or metastatic solid tumors